Epidemiology of Echinocandin Resistance in Candida
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Echinocandins are the newest antifungal agents approved for use in treating Candida infections in the USA. They act by interfering with 1,3-β-d-glucan synthase and therefore disrupt cell wall production and lead to Candida cell death. There is no intrinsic resistance to echinocandins among Candida species, and isolates from historic collections archived before the release of the echinocandins show no resistance. Resistance to the echinocandins remains low among most Candida species and ranges overall from 0 to 1 %. Among isolates of Candida glabrata, the proportion of resistant isolates is higher and has been reported to be as high as 13.5 % in at least one hospital. Antifungal resistance is due to specific amino acid mutations in the Fksp subunit(s) of the 1,3-β-d-glucan synthase which are localized to one of two hot spots. These mutations are being recognized in isolates from patients who have failed echinocandin therapy and often lead to a poor outcome. While the future looks bright for the echinocandins against most Candida species, C. glabrata remains a species of concern and resistance rates of C. glabrata to the echinocandins should be monitored closely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 3×
“The question lies in whether, as Alexander and coworkers [25] concluded after finding that every C.”
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Self-citationLortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323 · cited 1×
“parapsilosis has an intrinsic variation in its FKS sequence that coincides with a hot spot mutation [20], and the mechanisms of Candida lusi taniae and C.”
The changing epidemiology of healthcare-associated candidemia over three decades
Diekema, D., Arbefeville, S., Boyken, L., Kroeger, J., & Pfaller, M. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.001 · Cited by 309
Lockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
Self-citationCurrent Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274 · cited 1×
“Echinocandins, caspofungin, micafungin, and anidulafungin, act through noncompetitive inhibition of 1,3-β-D-glucan synthase, the enzyme responsible for the production of 1,3-β-Dglucan, a component of the cell wall in many species of fungus [2, 3].”
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01079-10 · Cited by 238 · cited 1×
“albicans resistance rates were still very low in nosocomial cases [45].”
Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237
National Surveillance of Fungemia in Denmark (2004 to 2009)
Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-10 · Cited by 223
Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216 · cited 1×
“It should also be noted that while there are always questions as to the consistency of antifungal susceptibility results between testing sites, caspofungin MICs are notoriously variable, and there is some doubt as to whether they can be relied upon at all [32].”
Self-citationElevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-12 · Cited by 214 · cited 3×
“Increased chitin content was also found in a lab strain ofC. glabrata treatedwith caspofungin [15], but in a separate study, it was not found in several clinical C. glabrata strains grown with caspofungin at each isolate’s IC50 [14].”
Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo
Lee, K. K., MacCallum, D. M., Jacobsen, M. D., Walker, L. A., Odds, F. C., Gow, N. A. R., & Munro, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00683-11 · Cited by 209
Arendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206 · cited 2×
“Many studies will not capture the isolates that develop echinocandin resistance over the course of treatment [35, 38], isolates which have been described in multiple publications [39, 40].”
Katiyar, S. K., Alastruey-Izquierdo, A., Healey, K. R., Johnson, M. E., Perlin, D. S., & Edlind, T. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00813-12 · Cited by 148 · cited 1×
“These mutations, first described in Candida isolates in 2005 [5], occur in one of two areas, hot spot 1, located at amino acids 641–649 in Candida albicans [6], and hot spot 2, located at amino acids 1345–1365 [7].”
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
Self-citationCandida spp. with Acquired Echinocandin Resistance, France, 2004–20101
Dannaoui, E., Desnos-Ollivier, M., Garcia-Hermoso, D., Grenouillet, F., Cassaing, S., Baixench, M.-T., Bretagne, S., Dromer, F., Lortholary, O., & the French Mycoses Study Group (2012) · Emerging infectious diseases · doi:10.3201/eid1801.110556 · Cited by 130 · cited 2×
“Many studies will not capture the isolates that develop echinocandin resistance over the course of treatment [35, 38], isolates which have been described in multiple publications [39, 40].”
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117 · cited 1×
“It has been demonstrated, however, that substitutions at different amino acids, even within the same hot spots, can have different impacts on resistance profiles, in terms of which echinocandins are affected and the extent of the decrease in susceptibility [11, 12].”
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109 · cited 2×
“glabrata, Candida parapsilosis, Candida tropicalis, Candida krusei, Candida dubliniensis, andCandida guilliermondii [7, 8].”
Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00136-13 · Cited by 105 · cited 1×
“glabrata, the presence of FKS mutations was significantly associated with treatment failure [9, 10].”
Lewis, J. S., Wiederhold, N. P., Wickes, B. L., Patterson, T. F., & Jorgensen, J. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01144-13 · Cited by 101
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80 · cited 1×
“glabrata has been noted by many studies [35, 42, 43, 38, 44] and has been attributed to widespread use of fluconazole, to which C.”
CRS–MIS in Candida glabrata: sphingolipids modulate echinocandin–Fks interaction
Healey, K. R., Katiyar, S. K., Raj, S., & Edlind, T. D. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08194.x · Cited by 79
Muller, H., Thierry, A., Coppée, J.-Y., Gouyette, C., Hennequin, C., Sismeiro, O., Talla, E., Dujon, B., & Fairhead, C. (2009) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.11.006 · Cited by 78
Cota, J. M., Grabinski, J. L., Talbert, R. L., Burgess, D. S., Rogers, P. D., Edlind, T. D., & Wiederhold, N. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01542-07 · Cited by 69 · cited 1×
“glabrata treatedwith caspofungin [15], but in a separate study, it was not found in several clinical C.”
Lackner, M., Tscherner, M., Schaller, M., Kuchler, K., Mair, C., Sartori, B., Istel, F., Arendrup, M. C., & Lass-Flörl, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00123-14 · Cited by 67 · cited 1×
“Furthermore, more than one of these mutations can occur in the same isolate, producing a less susceptible phenotype than would result from either mutation singularly [13, 12].”
Shields, R. K., Nguyen, M. H., Press, E. G., Updike, C. L., & Clancy, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01451-13 · Cited by 56
Marcos-Zambrano, L. J., Escribano, P., Sánchez, C., Muñoz, P., Bouza, E., & Guinea, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02670-14 · Cited by 49
EUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole
Cavling Arendrup, M., Cuenca‐Estrella, M., Lass‐Flörl, C., Hope, W. W., & The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST‐AFST) (2014) · Mycoses · doi:10.1111/myc.12170 · Cited by 43
Cited by
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Acquired multidrug antifungal resistance in Candida lusitaniae during therapy
Asner, S. A., Giulieri, S., Diezi, M., Marchetti, O., & Sanglard, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02204-15 · Cited by 82
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Post-transcriptional control of antifungal resistance in human fungal pathogens
Sharma, C., & Kadosh, D. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2080527 · Cited by 6
“(Grossman et al. 2014).”
Metadata
- Authors
- Grossman, N. T., Chiller, T. M., & Lockhart, S. R.
- Venue
- Current Fungal Infection Reports
- Published
- 2014-09-21
- Volume
- 8
- Issue
- 4
- Pages
- 243-248
- ISSN
- 1936-3761 (ISSN-L)
- 1936-377X
- OpenAlex
- W2043192385
- Cited by
- 28
- References
- 30
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.